Maria Elizabeth Menezes

Maria Elizabeth Menezes

Auto-generated profile, based on publicly available information

Maria Elizabeth Menezes

Coordenação de Ensino e Pesquisa (COEPE), Secretaria de Estado da Saúde de Santa Catarina, Brasil

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2007 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
CSCláudia Maria Dornelles da Silva
Cláudia Maria Dornelles da Silva
CCCintia Costi
Cintia Costi
LKLuciano Percival Krug
Luciano Percival Krug
ARAna Beatris Ramos
Ana Beatris Ramos
TGTarciana Grandi
Tarciana Grandi
MRMaria Lucia Rosa Rossetti
Maria Lucia Rosa Rossetti
Hepatitis C virus (HCV) isolates have been divided into six genotypes (1 to 6). The duration of hepatitis C standard treatment is 48 weeks for patients infected with HCV genotype 1 vs 24 weeks for those infected with genotypes 2 and 3. A total of 1544 HCV isolates from chronic patients living in the southern Brazilian states of Rio Grande do Sul (RS, n = 627) and Santa Catarina (SC, n = 917) were genotyped by restriction fragment length polymorphism (RFLP) of polymerase chain reaction (PCR) products. In RS, 338 (53.9%; 95% CI 50.0 - 57.8%), 34 (5.4%; 95% CI 3.8 - 7.4%) and, 255 (40.7%; 95% CI 36.9 - 44.6%) samples were from genotypes 1, 2, and 3, respectively. In SC, 468 (51%; 95% CI 47.8 - 54.2%), 26 (2.9%; 95% CI 1.9 - 4.1%) and, 423 (46.1%; 95% CI 42.9 - 49.3%) samples were from genotypes 1, 2, and 3, respectively. Genotyping results were confirmed by direct nucleotide sequencing of PCR products derived from 68 samples, without any discrepancy between PCR-RFLP and nucleotide sequencing methods. In conclusion, almost half of the hepatitis C patients from South of Brazil are infected by genotypes 2 and 3 and, these results have important consequential therapeutic implications as they can be treated for only 24 weeks, not 48.

1 January 2022 in Jornal Brasileiro de Doenças Sexualmente Transmissíveis
Verified
Journal Article
Open access
PDF file
EFEdison Natal Fedrizzi
Edison Natal Fedrizzi
SSSérgio Murilo Steffens
Sérgio Murilo Steffens
MMMaria Elizabeth Menezes
Maria Elizabeth Menezes
JLJosé Eduardo Levi
José Eduardo Levi
Introduction: Human Papillomavirus (HPV) infection is the most common sexually transmitted infection in women. About 80% of sexually active women will have contact with this virus at some point in their lives. Most infections will be transient, but when the infection becomes persistent and associated with a high oncogenic risk of Human Papillomavirus, there may be progression to cancer, especially cervical cancer. The best way to prevent Human Papillomavirus infection is through the use of vaccines, which have been available to the public in Brazil since 2014. Objective: This study aimed to assess the most prevalent types of Human Papillomavirus in the state of Santa Catarina, Brazil, and its mesoregions and if the majority of diagnosed types are contained in the Human Papillomavirus vaccines currently available on the market. Methods: A total of 20,000 Human Papillomavirus tests were evaluated for the diagnosis of genital Human Papillomavirus infection in women from the state of Santa Catarina, Brazil. The prevalence of infection was evaluated according to age and the city of origin of the exams. Human Papillomavirus detection was performed using molecular biology tests, such as hybrid capture (for diagnosis of the Human Papillomavirus group, high or low oncogenic risk) and polymerase chain reaction (viral genotyping) techniques. Results: The diagnosis of Human Papillomavirus infection was performed on women between 1 and 102 years of age. The age with the highest Human Papillomavirus positivity, as expected, was 20–25 years (45.6%) and the lowest after 70 years (7.1%). The highest Human Papillomavirus positivity of the exams was observed in the Serrana region of Santa Catarina state (58.9% of the exams). A high-oncogenic-risk Human Papillomavirus was detected in 93% of positive samples and was the most frequent in all age groups. Mixed infection (high- and low-risk Human Papillomavirus) was more prevalent in the 66–70 age group (29.3%) and in the Southern Region of Santa Catarina (26.4%). The most frequent genotypes in the state of Santa Catarina were non-16/18 high oncogenic risk Human Papillomavirus (76.9% of positive cases). Human Papillomavirus 16 was found in 17.1% of positive cases and Human Papillomavirus 18 in 6.6%. Conclusion: The most prevalent types of Human Papillomavirus in the state of Santa Catarina in the past 6 years are the non-16/18 high oncogenic risk Human Papillomavirus types, which are viral types not covered by the current Human Papillomavirus vaccines available in Brazil.

1 January 2023 in Jornal Brasileiro de Doenças Sexualmente Transmissíveis
Verified
Journal Article
Open access
PDF file
PCPâmela Raquel Conradesque
Pâmela Raquel Conradesque
IDIane Dagostin
Iane Dagostin
EFEdison Natal Fedrizzi
Edison Natal Fedrizzi
SSSérgio Murilo Steffens
Sérgio Murilo Steffens
PSPaula Fernanda Santos
Paula Fernanda Santos
MMMaria Elizabeth Menezes
Maria Elizabeth Menezes
Introduction: The human papillomavirus (HPV) is the most common sexually transmitted infection among women. The HPV of high oncogenic risk, associated with other factors, presents a risk of progressing to a precancerous lesion of the uterus and even cancer. Such an evolution is related to the persistence of the infection and other factors, mainly those that interfere with women’s immunity. The immunosuppression caused by HIV infection is an important factor for viral persistence and the onset of these lesions. Objectives: To compare the prevalence of HPV infection and cervical intraepithelial lesions in HIV-positive and negative women and describe the possible associated risk factors. Methods: The sample consisted of 50 HIV positive women (study group) and 50 HIV negative women (control group) recruited from the public health system of Florianópolis from January to April 2022. Cervical samples were collected for cytological analysis and for the detection of high-risk oncogenic HPV DNA by polymerase chain reaction (PCR). Categorical variables were compared using the chi-square test, with a significance level set at 5% Results: HPV infection was more prevalent in the control group; however, HIV positive women presented higher frequency of intraepithelial lesions diagnosed on cytology. Factors such as higher number of sexual partners, depression and smoking were more frequent in the group of HIV positive women. CD4 T cells lower than 200 cells/mm3 was associated with a higher number of altered Pap smears and a positive HPV DNA test. The use of combination antiretroviral therapy and undetectable viral load were associated with more frequent normal cytology and undetected HPV DNA. Conclusion: The prevalence of cervical intraepithelial lesions in HIV-infected women is higher than among women without the infection. The presence of HIV infection was the most important risk factor associated with the development of cervical lesions.

1 October 2026 in Revista Multidisciplinar do Nordeste Mineiro
Verified
Journal Article
Open access
PDF file
JFJoão Fernandes Floriano
João Fernandes Floriano
MMMaria Elizabeth Menezes
Maria Elizabeth Menezes
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonism have been proposed as candidate interventions against cognitive decline. This structured critical review appraises clinical, epidemiological, pharmacological and biomarker evidence through 23 September 2026 and examines why favourable prevention signals diverge from negative disease-modification trials. Pooled cardiovascular-trial data and a later, partly overlapping randomized-trial meta-analysis suggest fewer dementia events, recorded as secondary or safety outcomes, with GLP-1RAs, whereas target-trial emulations remain vulnerable to channelling, surveillance and residual confounding. A quantitative E-value sensitivity analysis shows marked variation in robustness across key observational estimates, from weak confidence-bound robustness in several comparisons to effect estimates so large as to be causally implausible and compatible with structural bias. In EVOKE and EVOKE+ (n=3,808), oral semaglutide did not slow Clinical Dementia Rating-Sum of Boxes progression at 104 weeks despite modest changes in cerebrospinal-fluid Alzheimer-related biomarkers. The phase 2b liraglutide trial in AD and the phase 3 exenatide trial in Parkinson's disease were also negative on their primary outcomes. We compare four competing explanations (disease stage, insufficient central exposure, confounded epidemiology and indirect vascular mediation) and specify evidence capable of discriminating among them. We further formalize a hypothesis-generating, stage-dependent Metabolic Window Hypothesis with explicit predictions and refutation conditions, and propose a Precision Incretin-Neurodegeneration Framework as a provisional operational scaffold for biomarker-stratified research. Neither semaglutide nor tirzepatide is an established therapy for preventing or treating Alzheimer's disease or dementia.

1 October 2026 in Revista Multidisciplinar do Nordeste Mineiro
Verified
Journal Article
Open access
PDF file
JFJoão Fernandes Floriano
João Fernandes Floriano
MMMaria Elizabeth Menezes
Maria Elizabeth Menezes
Introduction: Clinical pharmacogenomic guidelines are available, but implementation in Brazil's Unified Health System (SUS) faces testing costs, fragmented care pathways and limited reuse of results. Objective: To examine the determinants of pharmacogenomic costs and value in the SUS and to propose FARMA-GEN SUS, an author-proposed implementation model not adopted by the Ministry of Health, combining a multigene panel triggered by a first high-yield clinical indication, interoperable records and pharmacist–prescriber collaboration. Methods: Critical, proposal-oriented essay integrating clinical trials, economic evaluations, Brazilian population studies and regulatory documents in force on 13 October 2026, supplemented by targeted PubMed and BVS/LILACS searches. Published evidence, illustrative calculations and implementation proposals were considered separately; no primary clinical data were collected. Synthesis: In PREPARE, clinically relevant adverse drug reactions among patients with actionable gene–drug interactions occurred in 21.0% of the guided group versus 27.7% of controls (OR 0.70; 95% CI 0.54–0.91). The associated economic analysis identified the test price as a major cost driver, without establishing savings for Brazil. The proposed model prioritises high-yield clinical triggers, fit-for-purpose analytical coverage, structured recording, clinical interpretation and later reuse. An illustrative CYP2C19–clopidogrel break-even exercise used hypothetical clinical assumptions and a non-significant effect from TAILOR-PCI; with median public-purchase prices (2025–2026), the annual incremental cost of ticagrelor far exceeded the break-even ceilings against clopidogrel, whereas a counterfactual against universal ticagrelor suggested possible savings. Results depend on effect size, medicine and test costs and the comparator; the exercise is not a cost-effectiveness study. Conclusion: Savings for the SUS have not been demonstrated. FARMA-GEN SUS should be evaluated in a prospective comparative pilot measuring health outcomes (events avoided, QALYs), safety, micro-costed expenditure, access, implementation and budget impact before any scale-up.